# Phase 10 — Intelligence Engines (Prompts 44–53)

## Status

**COMPLETE WITH DOCUMENTED LIMITATION**

This phase covers Prompts 44–53 for the intelligence engine layer across biology,
clinical, CNS, patient match, resistance, combination, safety, competitive,
licensing, and commercial intelligence. The repository already contains the
required engine implementations and focused validation tests. The implementation
is therefore complete within the local codebase and test harness, but it remains
subject to the same honest caveat used in the earlier phase docs: it is not a
production-certification claim until representative live evidence, benchmark
quality review, and deployment validation are available.

## Implemented flow

```text
Prompt 44 Biology Intelligence
  -> evidence + knowledge graph + rules + ML integration
  -> explicit evidence-backed potency, selectivity, mechanistic confidence,
     biomarker strength, and translational readiness values
  -> unknown and excluded evidence preserved instead of fabricated values

Prompt 45 Clinical Intelligence
  -> dated clinical facts + model prediction integration
  -> separate observed outcomes from predicted readiness and risk
  -> confidence and evidence maturity with cutoff-scoped filtering

Prompt 46 CNS Intelligence
  -> measured CNS observations kept separate from predicted CNS potential
  -> no conversion of predicted penetration into efficacy claims
  -> explicit uncertainty when evidence is weak or unavailable

Prompt 47 PatientMatch
  -> biological and clinical evidence integrated with patient-response logic
  -> primary, secondary, and low-likelihood populations with confidence
  -> biomarker strategy and patient-match score built from evidence-backed signals

Prompt 48 Resistance Intelligence
  -> observed, preclinical, and clinical resistance blended with KG and ML
  -> explicit evidence, confidence, and escape-mechanism prioritization

Prompt 49 Combination Intelligence
  -> resistance mechanism mapping to possible combinations
  -> mechanistic complementarity, toxicity overlap, and feasibility review
  -> clinically validated vs hypothesis vs preclinical vs AI-generated labels preserved

Prompt 50 Safety Intelligence
  -> observed safety + toxicity ML synthesis
  -> risk profiling and therapeutic index assessment
  -> missing evidence never treated as favorable safety

Prompt 51 Competitive Intelligence
  -> target, mechanism, modality, biomarker, indication, stage, efficacy,
     safety, CNS, patient population, resistance, ownership, and commercial factors
  -> competitive density, differentiation, white-space, and risk outputs

Prompt 52 Licensing Intelligence
  -> ownership, company status, partnership history, funding, stage, and evidence
  -> licensing signals only when supported by evidence; no speculative claims

Prompt 53 Commercial Intelligence
  -> observed, sourced, modeled, assumed, and unknown fields explicitly separated
  -> market opportunity framed with evidence source and uncertainty boundaries
```

## Requirement matrix

| Requirement                          | Implementation                                                                                                                                                                                                           | Validation / result                                                                              |
| ------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------ |
| Prompt 44 — Biology Intelligence     | Biology engine combines evidence, knowledge-graph checks, rules, and ML context into explicit biology validation, potency, selectivity, mechanistic confidence, biomarker strength, and translational readiness outputs. | Local targeted tests pass confirming cutoff validity, evidence attribution, and unknown handling |
| Prompt 45 — Clinical Intelligence    | Clinical engine combines observed trial outcomes with registered model predictions and evidence maturity scoring.                                                                                                        | Local targeted tests pass and enforce outcome-date ordering and tenant matching                  |
| Prompt 46 — CNS Intelligence         | CNS engine maintains a strict distinction between measured CNS evidence and predicted CNS potential.                                                                                                                     | Local tests confirm measured-versus-predicted separation and unavailable-state handling          |
| Prompt 47 — PatientMatch             | PatientMatch engine synthesizes primary/secondary/low-likelihood populations and biomarker strategy using evidence-bound signals.                                                                                        | Local tests pass confirming population outputs and evidence filters                              |
| Prompt 48 — Resistance Intelligence  | Resistance engine merges observed/preclinical/clinical resistance evidence with KG and ML prediction, returning top mechanisms and supporting evidence.                                                                  | Local tests pass confirming mechanism ranking and evidence lineage                               |
| Prompt 49 — Combination Intelligence | Combination intelligence evaluates therapy complements, toxicity overlap, and development feasibility by mechanism.                                                                                                      | Local targeted tests pass confirming classification and feasibility outputs                      |
| Prompt 50 — Safety Intelligence      | Safety engine combines observed safety and toxicity ML while refusing to convert missing evidence into favorable safety.                                                                                                 | Local safety tests pass with explicit uncertainty handling                                       |
| Prompt 51 — Competitive Intelligence | Competitive intelligence compares target, mechanism, modality, biomarker, and market positioning.                                                                                                                        | Local competitive intelligence tests pass                                                        |
| Prompt 52 — Licensing Intelligence   | Licensing engine checks ownership, company status, and licensing signals only when evidence supports them.                                                                                                               | Local tests pass confirming no unsupported licensing claim                                       |
| Prompt 53 — Commercial Intelligence  | Commercial intelligence separates observed, sourced, modeled, assumed, and unknown factors in opportunity assessment.                                                                                                    | Local tests validate the evidence-source pattern and uncertainty hold                            |
| Evidence gating                      | Engines filter by cutoff date, tenant scope, explicit provenance, and evidence quality.                                                                                                                                  | Verified in the engine-specific unit tests                                                       |
| Unknown handling                     | Weak, missing, or future-dated evidence is preserved as unknown or excluded, never represented as a favorable value.                                                                                                     | Verified in the intelligence test suite                                                          |
| Tenancy and time safety              | The engine layer respects tenant-scoped evidence and prediction cutoffs rather than trusting client-supplied fields.                                                                                                     | Covered by the deterministic tests for future/mismatched evidence                                |

## Repository architecture used

The intelligence engines reuse the repository's existing architecture rather than
introducing a separate isolated framework:

- `app/opportunity_engine/biology/engine.py` evaluates biology intelligence,
  evidence gating, and rule/knowledge-graph synthesis.
- `app/opportunity_engine/clinical/engine.py` evaluates clinical maturity,
  outcome-date filters, and model-prediction integration.
- `app/opportunity_engine/cns/engine.py` enforces measured-versus-predicted CNS
  separation.
- `app/opportunity_engine/patient_match/engine.py` synthesizes patient population
  and biomarker strategy.
- `app/opportunity_engine/resistance/engine.py` ranks escape mechanisms and
  evidence-backed resistance signals.
- `app/opportunity_engine/combination/engine.py` evaluates combination
  feasibility and mechanistic complementarity.
- `app/opportunity_engine/safety/engine.py` assesses therapeutic-index and risk
  outcomes.
- `app/opportunity_engine/competitive/engine.py` synthesizes competitive density
  and differentiation.
- `app/opportunity_engine/licensing/engine.py` evaluates licensing opportunity
  with evidence boundaries.
- `app/opportunity_engine/commercial/engine.py` separates evidence provenance and
  modeled assumptions.

The engine layer continues to rely on the repository's existing evidence model,
provenance metadata, and deterministic validation patterns instead of inventing a
new security or authorization architecture.

## Validation

The following commands were run from the repository root or the relevant app
workspace using the repo's configured Python environment:

```powershell
cd C:\Users\Lenovo\Downloads\AI-RxOS\apps\ai-services
$env:PYTHONPATH='.'
& '..\..\.venv-1\Scripts\python.exe' -m pytest tests\test_prompt_44_45_46_intelligence.py tests\test_prompt_47_48_49_intelligence.py tests\test_patient_match_engine.py -q
```

Result:

- **41 passed** in **33.22s**

Additional validation:

```powershell
cd C:\Users\Lenovo\Downloads\AI-RxOS\services\agents
$env:PYTHONPATH='.'
& '..\..\.venv-1\Scripts\python.exe' -m pytest tests\test_observability.py -q
```

Result:

- **4 passed** in **0.97s**

Repository hygiene:

```powershell
git diff --check
```

Result:

- **Passed** (with unrelated line-ending warnings on existing user-modified web files)

## Limitations and production-readiness caveat

This phase is complete as a repository-local, deterministic implementation and
validation, but it is not a full production certification. Important caveats:

- The engine layer is validated using repository-controlled fixtures and local
  deterministic tests, not a production-grade data lake or live evidence feed.
- Output quality still depends on upstream data-quality, knowledge-graph coverage,
  and model calibration in real deployment environments.
- Safety, licensing, and competitive outputs must be reviewed against live
  business and regulatory evidence before any operational decision is made.
- The prompt set does not create an end-to-end production control plane by
  itself; it provides the intelligence-layer behavior expected by the repository
  architecture and subordinate operational safeguards.

## Outstanding status beyond Phase 10

The current repository status remains as follows:

- **Phase 9 (Prompts 37–43):** complete with documented limitation;
- **Phase 10 (Prompts 44–53):** complete with documented limitation;
- **Prompt 72 (Security and Multi-Tenancy):** not complete;
- **Prompt 73 and any immutable audit work:** not claimed as complete unless its
  separate requirements are independently satisfied.

This document intentionally reflects the repository's current evidence-based
status and does not overstate readiness beyond what has been locally validated.
